Locals can expect better access to essential medicines thanks to a significant funding increase for Pharmac.

Associate Health Minister David Seymour announced that the Government’s recent investment will substantially improve medicine availability across New Zealand.

Pharmac, the Crown entity responsible for medicine and medical device funding, had faced a challenging financial situation.

“Pharmac operates independently, but it must work within the budget constraints set by the Government,” Seymour stated.

“When our Government assumed office, Pharmac had a $1.7 billion funding gap and no new resources to improve medicine access.”

In response, the Government has allocated a record $6.294 billion to Pharmac over the next four years.

This unprecedented funding aims to enhance Pharmac’s capacity to secure better deals for medications.

As of 28 August 2024, Pharmac has reviewed funding for 24 treatments, including 13 for cancer and 11 for other conditions.

Starting 1 October 2024, several new treatments will be funded, including Keytruda for advanced cancers such as triple-negative breast cancer, head and neck cancer, and advanced bladder cancer.

Opdivo will also be available from 1 November 2024 for those with advanced kidney cancer.

Additionally, there will be expanded access to preventative treatments like posaconazole and voriconazole for immunocompromised patients.

This follows earlier decisions to fund ten new medicines for 2024/25 and to provide Continued Glucose Monitors (CGMs) and insulin pumps from 1 October.

Seymour praised Pharmac’s efforts, highlighting the positive impact on patients and their families.

“I’m pleased to see Pharmac’s responsiveness to patient needs, particularly with expanded access to Keytruda for various cancer types. This reflects our commitment to a more adaptable and patient-centred health system.”

Pharmac remains an independent entity, but the Government’s increased funding marks a significant shift towards improving medicine access and overall healthcare quality in New Zealand.